Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -254.86% is 42% above its 5-year average of -441.92%, near the high end of its 5-year range (-61951.22%–-53.54%).
8.56% above its 12-month average of -278.71%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -53.54%.
EBITDA MARGIN
-254.86%
EBITDA MARGIN AVG TTM
-278.71%
EBITDA MARGIN AVG 3Y
-374.43%
EBITDA MARGIN AVG 5Y
-441.92%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+8.56%
CURRENT VS 3Y AVG
+31.93%
CURRENT VS 5Y AVG
+42.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Foghorn Therapeutics Inc.
Market Cap
$114.20M
EBITDA Margin
-254.86%
TTM Avg
-278.71%
3Y Avg
-374.43%
5Y Avg
-441.92%
Market Cap
$113.55M
EBITDA Margin
-121.55%
TTM Avg
-120.84%
3Y Avg
-101.07%
5Y Avg
-82.00%
Market Cap
$115.93M
EBITDA Margin
-1036.29%
TTM Avg
-1034.54%
3Y Avg
-4587.22%
5Y Avg
-4766.38%
Market Cap
$115.77M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$116.14M
EBITDA Margin
-408000.00%
TTM Avg
-396456.25%
3Y Avg
-201636.71%
5Y Avg
-201636.71%
Market Cap
$116.82M
EBITDA Margin
-254.71%
TTM Avg
-369.64%
3Y Avg
-290.17%
5Y Avg
-290.17%
Market Cap
$117.03M
EBITDA Margin
-1187.82%
TTM Avg
-1407.84%
3Y Avg
-970.99%
5Y Avg
-809.42%
Market Cap
$109.86M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.07M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $114.20M | -254.86% | -278.71% | -374.43% | -441.92% |
| MaxCyte, Inc. (MXCT)vs › | $113.55M | -121.55% | -120.84% | -101.07% | -82.00% |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.93M | -1036.29% | -1034.54% | -4587.22% | -4766.38% |
| BGM Group Ltd. (BGM)vs › | $115.77M | -29.32% | -13.32% | -6.17% | -1.07% |
| Genelux Corporation (GNLX)vs › | $116.14M | -408000.00% | -396456.25% | -201636.71% | -201636.71% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.82M | -254.71% | -369.64% | -290.17% | -290.17% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | -1187.82% | -1407.84% | -970.99% | -809.42% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.86M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.07M | -10.96% | -24.45% | -32.87% | -38.11% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.05M | -475.96% | -475.96% | -272.89% | -272.89% |
Gross Margin
89.2%
EBITDA Margin
-254.9%
Operating Margin
-265.6%
Net Margin
-175.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -53.54% |
| 2026-03-31 | -653.05% |
| 2025-12-31 | -203.24% |
| 2025-09-30 | -216.47% |
| 2025-06-30 | -267.26% |
| 2025-03-31 | -371.07% |
| 2024-12-31 | -813.87% |
| 2024-09-30 | -296.09% |
| 2024-06-30 | -375.16% |
| 2024-03-31 | -541.76% |
| 2023-12-31 | -426.52% |
| 2023-09-30 | -92.79% |
| 2023-06-30 | -556.78% |
| 2023-03-31 | -611.38% |
| 2022-12-31 | -741.83% |
| 2022-09-30 | -413.26% |
| 2022-06-30 | -631.83% |
| 2022-03-31 | -688.60% |
| 2021-12-31 | -3824.96% |
| 2021-09-30 | -61951.22% |
| 2021-06-30 | -8056.27% |
| 2021-03-31 | -7817.48% |
| 2020-12-31 | -8054.18% |
| 2020-09-30 | -10186.59% |
